On Sept. 15, 2021, InBios announced that it had received Emergency Use Authorization from the U.S. Food and Drug Administration for its SCoV-2 Detect IgG Rapid Test, a qualitative immunoassay for the detection of IgG antibodies to SARS-CoV-2.

The test can be performed using serum, plasma (sodium citrate, dipotassium EDTA, or sodium heparin treated), venous whole blood (sodium citrate, dipotassium EDTA or sodium heparin treated) or fingerstick whole blood samples and takes about 20 minutes to obtain results.

This marked InBios’ fifth EUA granted for SARS-CoV-2 diagnostics since the beginning of the COVID-19 pandemic.